Background of Ziihera's FDA Approval for First-Line Treatment of HER2-Positive GEA

Ziihera (zanidatamab-hrii), a HER2-targeting bispecific antibody developed by Jazz Pharmaceuticals, received final FDA approval on August 25, 2026, as a first-line therapy for HER2-positive gastric/GE junction adenocarcinoma (GEA). This approval was based on positive data from the Phase 3 'HERIZON-GEA-01' trial, which demonstrated superior clinical efficacy compared to the standard of care (SoC) regimen of trastuzumab in combination with chemotherapy. With this approval, Ziihera expands its therapeutic footprint beyond the second-line biliary tract cancer (BTC) indication it received accelerated approval for in November 2024, into the broader first-line GEA market. This marks a pivotal moment in oncology, reinforcing the industry's shift from monoclonal to bispecific antibody therapies in HER2-targeted treatment paradigms.

Clinical Advantages Over Comparator and Their Value

In the global Phase 3 'HERIZON-GEA-01' trial, the combination of Ziihera with chemotherapy showed statistically significant survival benefits over the comparator arm of trastuzumab plus chemotherapy. The median progression-free survival (mPFS) for the Ziihera combination group was 12.4 months, compared to 8.1 months in the control group, reducing the risk of disease progression or death by over 35%. Notably, the triple regimen combining Ziihera with the PD-1 inhibitor tislelizumab and chemotherapy achieved a median overall survival (mOS) of 26.4 months, a 7.2-month survival advantage over the control group's 19.2 months (hazard ratio 0.72). These impressive survival outcomes are being hailed as a breakthrough for patients with metastatic GEA, a population with historically poor prognosis and limited treatment options.

Licensing Agreement with Zymeworks and $250M Milestone Triggered

The FDA's final approval triggered a major financial milestone under Jazz Pharmaceuticals' licensing agreement with Zymeworks. Upon fulfilling the regulatory approval criteria, Jazz Pharmaceuticals is obligated to pay Zymeworks a $250 million regulatory milestone payment. The two companies had previously completed an upfront payment of $50 million and an option exercise fee of $325 million, totaling $375 million in initial cash transactions. Additional milestones of up to $1.3 billion are expected to be paid based on future commercial progress. Combined with tiered royalties of 10–20% of future Ziihera sales, Zymeworks is now well-positioned to secure sustainable R&D funding and accelerate its mid-to-long-term growth trajectory.

Competitive Landscape and Commercial Outlook in the HER2-Positive GEA Market

The global market for HER2-positive gastric and gastroesophageal junction cancer therapies is currently valued at approximately $1.3–1.4 billion annually and is projected to grow rapidly to over $2.3 billion in the 7MM (major 7 markets) in the coming years. Ziihera is emerging as a strong alternative in the first-line treatment space, which has been dominated by the trastuzumab and pembrolizumab combination, and is expected to intensify competition for market share. While the antibody-drug conjugate (ADC) Enhertu holds a solid position in the second-line setting, Ziihera is anticipated to gain physician preference due to its superior efficacy in first-line treatment and manageable safety profile (notably, diarrhea and infusion-related reactions). Overall, Ziihera is expected to diversify Jazz Pharmaceuticals' oncology portfolio and serve as a key revenue driver for the company in the coming years.